We are excited to share that the NYSE joined us in celebrating the successful closing of our $144M Series B financing on their Trading Floor last week! This significant milestone will accelerate the clinical development of our AI-powered cell therapies for patients battling #ovariancancer and other #solidtumors. Additionally, this financing will support the further expansion of our pipeline and platform. Read more here: https://lnkd.in/eimM3UZi Thank you to all our investors and partners for your support. We look forward to working together to deliver on the promise of #celltherapy in #solidtumors with unrivaled #AI-powered #proteindesign. The #SeriesB #financing brings our total capital raised to approximately $200 million and was led by RA Capital Management, with participation from new investors Qatar Investment Authority (QIA), Surveyor Capital (a Citadel company), Sheatree Capital, Black Opal Ventures, Alexandria Venture Investments (Alexandria Real Estate Equities, Inc.), and other undisclosed investors. Outpace’s existing investors ARTIS Ventures, Playground Global, Bristol Myers Squibb, Abstract Ventures, Civilization Ventures, Mubadala Capital, Breton Capital Ventures, Washington Research Foundation, Sahsen Ventures, LLC, also participated in the round. #oncology #biotech #syntheticbiology #seattle #Tcell #CART #TCR #celltherapy #NYSE Eric J. Dimise, PhD
Outpace Bio
Biotechnology Research
Seattle, Washington 4,016 followers
Revolutionizing Cell Therapy with Protein Design
About us
Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the potency (OutSpacers™), specificity (Co-LOCKR™), and safety (EGFRopt™) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes. At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.
- Website
-
http://www.outpacebio.com
External link for Outpace Bio
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Seattle, Washington
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Cell Therapy, Protein Design, Cell Engineering, Cytokines, and Immuno-oncology
Locations
-
Primary
700 Dexter Ave N
Suite 300
Seattle, Washington 98109, US
Employees at Outpace Bio
-
Alaa Halawa
Investing in and building transformative companies at the intersection of technology and healthcare
-
Josh Jarrett
Insurance, Marketing, Product/Actuarial, Analytics, Health & Fitness, Smartgyms, Blockchain
-
Eric Soller
CBO @ Outpace | Biotech Entrepreneur, former VC, former McK
-
Marc Lajoie
CEO at Outpace Bio
Updates
-
We look forward to participating in the Chardan 8th Annual Genetic Medicines Conference this week in #NYC. Our Co-Founder and CEO Marc Lajoie will give a presentation on Mon., Sep. 30 at 2 pm describing our latest advances in #programming #celltherapies for improved function inside patients battling #solidtumors using unrivaled #AI-powered #proteindesign. #ChardanGMConf #OutpaceBio #proteindesign #celltherapy #CART #TCRT #AI #syntheticbiology #oncology #solidtumors
-
🎙 Don't miss our CSO Aaron Foster at tomorrow's inaugural BioCentury Inc. #GrandRounds panel that highlights which #CART cell manipulation strategies are rising above the noise for #solidtumors including the latest from Outpace Bio's #AI-driven #proteindesign platform. Learn more: https://lnkd.in/gti9bfMf #celltherapy #CART #Tcell #oncology #cancer #proteindesign #AI #syntheticbiology #Outpace #biotech
-
Outpace Bio reposted this
Join us on September 19th for OUTbio Seattle's second mentoring event with board member Christian Dimaano. Our friends at Outpace Bio have invited us back to Dexter Yard to lead a queer career roundtable with leaders from the Seattle biotech scene. Bring your appetite for light bites and refreshments–and your burning questions for the leaders shaping Seattle's biotech industry from the bench to the boardroom. They’ll be on deck to share their insights and guidance. We have a limited number of tickets for this event, so grab yours while they’re available. Here’s the nitty gritty: 📅 Thursday, September 19 🕔 5:30 – 8:00 pm Pacific 🗺1000 Dexter Ave, 98109 🎟 Head to the comments for the ticket link
-
Today, we are thrilled to announce the successful closing of an oversubscribed Series B financing of $144M. This funding will propel the advancement of multiple programmed T cell product candidates to early clinical proof-of-concept in #ovariancancer and other #solidtumors, and further expand our pipeline and platform. We are also excited to welcome Jake Simson, PhD from RA Capital Management to our Board of Directors. Our lead program, OPB-101, is a mesothelin-specific CAR T cell enhanced by Outpace's proprietary technologies: OUTSMART™, OUTLAST™, OUTSPACER™, and OUTSAFE™. OPB-101 has shown complete elimination of solid tumors in stringent in vivo models at very low treatment doses (as low as 50,000 cells) and is on track for IND clearance and first dosing in 2025 for patients with advanced platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. We extend our gratitude to our world-class syndicate of investors for believing in and supporting our mission to revolutionize treatment outcomes for #patients battling #solidtumors. Read more in our press release: https://lnkd.in/eimM3UZi The Series B financing brings our total capital raised to approximately $200 million and was led by RA Capital Management, with participation from new investors Qatar Investment Authority (QIA), Surveyor Capital (a Citadel company), Sheatree Capital, Black Opal Ventures, Alexandria Venture Investments (Alexandria Real Estate Equities, Inc.), and other undisclosed investors. Outpace’s existing investors ARTIS Ventures, Playground Global, Bristol Myers Squibb Abstract Ventures, Civilization Ventures, Mubadala Capital, Breton Capital Ventures, Washington Research Foundation, Sahsen Ventures, LLC, also participated in the round. #proteindesign #celltherapy #oncology #solidtumors #AI #biotech #syntheticbiology #seattle #CAR #TCR
-
#SeattleTechWeek is here and we're excited to co-host Wednesday's "Meet the Protein Designers: Happy Hour & Networking Reception" at SLU BRU alongside Monod Bio, A-Alpha Bio, Xaira Therapeutics, and Bits in Bio. https://lu.ma/lx2bvjq3 Note: We have received overwhelming interest and the event is currently at capacity. Please update your registration if you are no longer able to join so we can welcome additional guests from the waitlist! #proteindesign #celltherapy #AI #seattletechweek #biotech #networking #seattle
-
🎤 Our hometown of #Seattle is the epicenter of #AI, #proteindesign, & #celltherapy and during tomorrow's #LSINW24 #Oncology track Outpace Bio CEO & Co-founder Marc Lajoie, PhD will take the stage to share an exciting update on our latest efforts to #reprogram #cells for optimal function inside patients. Don't miss an opportunity to join our community as we come together to discuss and feature some of the most compelling #lifesciences #breakthroughs of our time at the #PacificNorthwest's largest annual life science conference: Life Science Innovation Northwest (LSINW). Learn more: https://lnkd.in/gtm893b9 #LSINW2024 #biotech #Seattle #OutpaceBio #celltherapy #AI #proteindesign #CART #TCRT #oncology #cancer
-
🔬 At #AACR24 we're sharing new data on the use of AI-powered protein design to program T cell therapies for unprecedented efficacy against solid tumors. Learn more: https://lnkd.in/eUAeHFqN American Association for Cancer Research #OutpaceBio #proteindesign #AI #celltherapy #CART #CARTcells #oncology #solidtumors #cancer #cytokines #syntheticbiology #biotech #innovation #Seattle #AACR24
-
🎤 Catch Outpace Bio CSO Aaron Foster on how to successfully navigate cell therapy development at today’s panel “CAR-T Therapy Journey (from Discovery to Commercialization)” at the 2024 Charles River Laboratories #CGTsummit #cellandgenetherapy #advancedtherapies #cartcelltherapy #proteindesign #oncology #celltherapy
Today at the 2024 Cell and Gene Therapy Summit we are delighted to welcome leaders shaping the future of CGT development and will be kick-starting the day with incredible keynote presentations from the FDA's Dr. Peter Marks and NASA Ames Research Center's Dr. Sylvain Costes. Check out the full agenda: https://okt.to/LHYRxq Joining us? Please share your highlights and takeaways tagging Charles River Laboratories #CGTSummit #cellandgenetherapy #advancedtherapies #concepttocure
2024 Cell & Gene Therapy Summit
events.criver.com
-
🎤 At #PMWC24 today Brian Weitzner, Outpace Bio's head of computational & structural biology, will give an engaging talk on our latest efforts to create cell therapies for solid tumors with curative potential using our powerful AI-powered protein design platform. Don't miss it! Additional details below. Track: 1 Session: AI-enabled Approaches in Cell Therapy Time: 2:45 p PT Location: Santa Clara Convention Center #PMWC24 #AI #ProteinDesign #CancerResearch #CellTherapy #CARTcells #TCRtherapy #MedicalInnovation #Oncology #CancerTherapy #biotechnology